We hypothesized that prostate cancer screening and availability of urologists among states may be associated with reduced prostate cancer mortality in the United States. To test this hypothesis, statespecific prostate cancer mortality rates for white males were compared to urologist population densities and prostate-specific antigen (PSA) screening rates on a state-by-state basis. The urologist population density was calculated by dividing the number of urologists per state by the population. We found that prostate cancer mortality rates correlated inversely with urologist population densities (Po0.01) and PSA screening (Po0.01) suggesting that screening and treatment reduce prostate cancer mortality.
Introduction
Prostate cancer mortality rates vary among states in the United States and the causes are largely uncertain. Ageadjusted prostate cancer mortality rates for white males per 100 000 population varied from about 22 deaths per year in Florida to about 32 deaths per year for Alaska and Wyoming from 2000 to 2003. 1 Prostate-specific antigen (PSA) screening to identify high-risk prostate cancer patients for further treatment has been widely used since the late 1980s. Prostate cancer screening and treatment may be the cause of at least part of variation in prostate mortality rates among states but there is little data. Screening for prostate cancer by the use of PSA or digital rectal examinations is not currently recommended as a component of cancer control by a group tasked to make national recommendations on cancer prevention strategy. The US Preventive Services Task Force has concluded that the evidence is insufficient to make a recommendation for or against routine screening using PSA testing or digital rectal examinations. 2 The US Preventive Services Task Force cites the current lack of evidence that early detection improves health outcomes and the potential harm that can result from treatment.
Definitive evidence on the effects of prostate cancer screening on mortality and survival should come from the results of large-scale trials. The results from two randomized clinical trials, still ongoing, will provide additional information about the benefits and risks of screening for prostate cancer. 3, 4 In the interim, exploring the relationship between prostate cancer mortality and factors associated with prostate cancer screening and treatment may provide some indication as to whether urologic care provides risk-reduction benefits.
The objective of this study is to compare annual rates of prostate cancer mortality among states to urologist population density levels and PSA screening rates. We assume that the prevalence of urologists in the population is related to the amount of prostate cancer treatment afforded. We hypothesize that if prostate cancer screening and treatment are responsible for reducing prostate cancer mortality rates, then urologist population density levels and PSA screening rates among states may correlate inversely with mortality rates. To control for access to medical care and socioeconomic status, median family income, degree of urbanization and health insurance status will be included in the analysis. Degree of urbanization was selected as a factor for consideration in this study because hospitals and physicians are more likely to be located in urban areas. Urbanization exhibited an inverse correlation with prostate cancer mortality rates in at least one ecologic study. 5 
Materials and methods
Cancer mortality rates were obtained from the Surveillance, Epidemiology and End Results Program of the National Cancer Institute. 1 Cancer mortality rates cover deaths (all ages) from 2000 to 2003 and are age adjusted to a standard population (2000; the United States). Black males were not included in this study because the data were too sparse for national analyses.
Age-adjusted data among states for PSA screening levels (2002) and lack of health insurance coverage for white males (2001) (2002) (2003) were obtained from the Behavioral Risk Factor Surveillance System (BRFSS), an annual cross-sectional, population-based, random-digitdialed telephone survey given by the Centers for Disease Control and Prevention for tracking health-care use and risk behaviors at a state level. 6 Median family income levels and the percentage of people residing in an urban setting as opposed to a rural location for states were obtained from the US Census Bureau Data 7 for 2000. The number of urologists in each state was obtained from the member directory compiled by the American Urologic Association. Population densities of urologists were calculated by dividing the number of urologists by the population 7 of the state. Initially, all data were examined for normalcy and to identify outlier. All variables appeared to possess a normal distribution and there were no outliers. The population density of urologists varied from about 2 per 100 000 of population for North Dakota and Idaho to about 4.4 for New York and Maryland. Summary statistics for the variables in this study are provided in Table 1 . States with the highest and lowest values for variables are presented in Table 2 .
Prostate cancer mortality rates for states were compared to urologist population density levels; PSA screening rates; lack of health insurance coverage levels; median family income and degree of urbanization. Regression coefficients (B), correlation coefficients (R) and probability (P) values (two-sided) were calculated. Cross-correlations between the variables in this study were determined prior to conducting a multivariable linear regression analysis to determine the best-fit model for predicting prostate cancer mortality rates from the variables. The statistical analyses in this study were performed using the software program SPSS for Windows, version 12.0 by SPSS Inc. (Chicago, IL, USA).
Results
Prostate cancer mortality compared to the independent variables selected for this study are provided in Table 3 with regression coefficients (B) with 95% confidence intervals, correlation coefficients (R) and probability (P) values. Prostate cancer mortality rates correlated inversely with urologist population density; PSA screening and urbanization. The correlation was strongest with urologist population density and PSA screening rates. A plot of the data points for prostate cancer mortality rates against urologist population density is provided in Figure 1 ; and PSA screening levels is provided in Figure 2 . There was no statistically significant correlation between prostate cancer mortality and median family income or percentage of the population in states lacking health insurance.
Cross-correlations between the variables in this study are presented in Table 4 . Median family income correlated inversely with lack of health insurance coverage and directly with the degree of urbanization. Urologist population density correlated directly with median family income and inversely with lack of health insurance coverage.
A multivariable linear regression analysis found the best-fit model for prostate cancer mortality rates contained urologist population densities and PSA screening levels as independent variables. The regression coefficients with 95% confidence intervals for this model are urologist population density (B ¼ À1.2 (À2.1, À0.3)) and PSA testing ((B ¼ À0.2 (À0.3, À0.03)). The results are provided in Table 5 .
In each case, the effect of variation of urologist population density levels and PSA testing rates on prostate cancer mortality rates across the interquartile (from the 25th to the 75th percentile value) was calculated to put the results in perspective. This calculation was performed by multiplying the regression coefficient by the difference between the 25th percentile value and the 75th percentile value for each independent variable in the best-fit model. The effect of variation of Urologic care and prostate cancer rates JL Colli and CL Amling urologist population density or PSA testing, across half of the range of prostate cancer mortality rates, is about the same for each; about one death per year per 100 000 inhabitants (see Table 5 ).
Discussion
In this study, prostate cancer mortality rates exhibit a statistically significant inverse correlation with PSA screening rates and the population density of urologists suggesting that prostate cancer screening and urologic care are associated with reduced prostate cancer mortality rates among states. Further, our analysis suggests that these factors may be responsible for most of the variation in prostate cancer mortality from the 25th to the 75th percentile of prostate cancer mortality rates, about two deaths per year out of three. These results are generally consistent with past studies although the associations we found are somewhat stronger. An ecologic study of PSA screening and prostate cancer mortality in the United States suggested a weak association between PSA screening and prostate cancer mortality. 8 A recent study 9 exploring causes for declining prostate cancer mortality rates in the United States from 1993 to 2003 also found a correlation between PSA screening and prostate cancer mortality rates although the strength of the correlation was somewhat weaker than that found in the current study. The increased strength found in this study is may be due to the improved quality of BRFSS data for PSA screening rates among states in the 2002 time period as compared to earlier years.
The degree of urbanization also exhibits a strong correlation to prostate cancer mortality rates. Urologists (as well as other physicians) tend to be located in urban areas. The urologist population density values, averaged over the state in this study, do not take into account the range of values that occur within states. For example, we calculate that the District of Columbia has an urologist population density value of almost 13, reflecting a level Abbreviation: PSA, prostate-specific antigen. Regression coefficients (B) with 95% confidence intervals, correlation coefficients (R) and probability (P) values. Figure 1 Prostate cancer mortality versus urologist population density in US states.
Urologic care and prostate cancer rates JL Colli and CL Amling that is likely in many urban areas while sparsely populated rural areas may have much lower values. This suggests that there may be a wide variation in prostate mortality rates across states depending on urologist population density and degree of urbanization.
In one study that examined the association between geographic variations in prostate cancer mortality and regional variations in access to medical care, as reflected by the incidence of late-stage disease, PSA utilization and residence in rural counties, the authors concluded that residence in rural areas and the incidence of late-stage disease are inversely associated with the utilization of PSA testing. 10 These results are generally consistent with the current study which found that the degree of urbanization correlates inversely with prostate cancer mortality.
The lack of correlation between males lacking health insurance and either prostate cancer mortality rates was unforeseen. However there are several mitigating factors. Many males have access to Veterans Administration Medical Centers and do not rely on health insurance for prostate cancer care and treatment. Also, prostate cancer often occurs after age 65 when men have access to Medicare.
There are other factors that may contribute to the variation in prostate cancer mortality and should be mentioned. Farming has been associated with increased risk of prostate cancer. 11, 12 However, since farmers account for less than 1% of the population nationally, 7 it is unlikely that farming would affect prostate cancer mortality rates among states to a significant extent. In addition, farm-related occupations at the county level did not account for the excess regional risk in death rates from prostate cancer among white males in one study. 13 It has been proposed that UV radiation from sun exposure protects against prostate cancer and sunlight levels vary geographically. Sunlight causes the synthesis of vitamin D, which has been hypothesized to reduce the risk of prostate cancer.
14 However, studies on the role of vitamin D in the development of prostate cancer have been inconsistent.
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Figure 2 Prostate cancer mortality versus PSA Screening rates in US states. Table 5 Step-wise multiple regression analysis on age-standardized prostate cancer mortality rates against urologist population densities and PSA testing rates: regression coefficients (B) with 95% confidence intervals, probability values (P) and effect of the variable across the interquartile There are limitations to the ecologic approach taken in this study that may cause uncertainties in the results. The analyses are not based on individual data but on data representing an entire state. The use of data for the entire state rather than smaller geographic entities results does not take into consideration the range of values within the state. The limitations of this ecologic approach have been evaluated. 22 Also, data for some of the independent variables (PSA screening and lack of health insurance coverage) were self-reported through telephone interviews. The response rates widely vary across states and uncertainties in data that have been reported through telephone interviews have been reported. 23 Self-reported data used to determine cancer screening test utilization may also be inaccurate. 24 Despite these limitations, prostate cancer mortality rates correlated with several independent variables in a manner that were consistent with data in the literature.
Conclusions
Prostate cancer mortality rates correlate inversely with urologist population density and PSA screening rates among US states. These findings suggest that prostate cancer screening and urologic care are associated with reduced prostate cancer mortality risks and the variation in rates observed between states.
